Defective Mismatch Repair and Benefit from Bevacizumab for Colon Cancer: Findings from NSABP C-08

Kay POGUE-GEILE; Greg YOTHERS; Carmen ALLEGRA; Nicholas PETRELLI; Michael J O'CONNELL; Norman WOLMARK; SOONMYUNG PAIK; Yusuke TANIYAMA; Noriko TANAKA; Patrick GAVIN; Linda COLANGELO; Nicole BLACKMON; Corey LIPCHIK; Seong Rim KIM; Saima SHARIF

doi:10.1093/jnci/djt140

Back

Defective Mismatch Repair and Benefit from Bevacizumab for Colon Cancer: Findings from NSABP C-08

Journal article

Open access

Peer reviewed

Defective Mismatch Repair and Benefit from Bevacizumab for Colon Cancer: Findings from NSABP C-08

Kay POGUE-GEILE, Greg YOTHERS, Carmen ALLEGRA, Nicholas PETRELLI, Michael J O'CONNELL, Norman WOLMARK, SOONMYUNG PAIK, Yusuke TANIYAMA, Noriko TANAKA, Patrick GAVIN, …

JNCI : Journal of the National Cancer Institute, Vol.105(13), pp.989-992

2013

DOI: 10.1093/jnci/djt140

PMCID: PMC3699439

PMID: 23821759

Files and links (1)

url

https://doi.org/10.1093/jnci/djt140View

Published (Version of record) Open Access

Abstract

National Surgical Adjuvant Breast and Bowel Project protocol C-08 tested the worth of adding 1 year of bevacizumab to oxaliplatin-based standard adjuvant chemotherapy regimen in the treatment of stage II/III colon cancer. Although the overall result was negative, the possibility that a molecularly defined subset could benefit from bevacizumab cannot be ruled out. We performed post hoc Cox regression analyses to test for marker-by-treatment interactions for standard pathological features and survival analyses using the Kaplan-Meier method. All statistical tests were two-sided and considered statistically significant at the .05 level. Patients diagnosed with mismatch repair defective (dMMR) tumors derived statistically significant survival benefit from the addition of bevacizumab (hazard ratio [HR] = 0.52; 95% confidence interval [CI] = 0.29 to 0.94; P = .02) in contrast with no benefit in patients diagnosed with mismatch repair proficient tumors (HR = 1.03; 95% CI = 0.84 to 1.27; p = .78; P(interaction)= .04). Although a post hoc finding, this data suggests that a molecularly defined subset of colon cancer patients may derive clinical benefit from antiangiogenesis agents and underscores the need for independent validation in other clinical trials.

Immunotherapy

Antineoplastic Agents

Tumors

Pharmacology. Drug treatments

Biological and medical sciences

Multiple tumors. Solid tumors. Tumors in childhood (general aspects)

Medical sciences

Details

Title: Subtitle: Defective Mismatch Repair and Benefit from Bevacizumab for Colon Cancer: Findings from NSABP C-08
Creators: Kay POGUE-GEILE - National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh, PA, United States
Greg YOTHERS - National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh, PA, United States
Carmen ALLEGRA - National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh, PA, United States
Nicholas PETRELLI - National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh, PA, United States
Michael J O'CONNELL - National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh, PA, United States
Norman WOLMARK - National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh, PA, United States
SOONMYUNG PAIK - National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh, PA, United States
Yusuke TANIYAMA - National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh, PA, United States
Noriko TANAKA - National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh, PA, United States
Patrick GAVIN - National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh, PA, United States
Linda COLANGELO - National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh, PA, United States
Nicole BLACKMON - National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh, PA, United States
Corey LIPCHIK - National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh, PA, United States
Seong Rim KIM - National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh, PA, United States
Saima SHARIF - National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh, PA, United States
Resource Type: Journal article
Publication Details: JNCI : Journal of the National Cancer Institute, Vol.105(13), pp.989-992
DOI: 10.1093/jnci/djt140
PMID: 23821759
PMCID: PMC3699439
NLM abbreviation: J Natl Cancer Inst
ISSN: 0027-8874
eISSN: 1460-2105
Publisher: Oxford University Press
Language: English
Date published: 2013
Academic Unit: Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
Record Identifier: 9984094337902771

Metrics

20 Record Views

52 Times Cited - Web of Science